SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

CorMedix, Inc. is a pharmaceutical and medical device company, which engages in the development and commercialization of therapeutic products for the prevention and treatment of diseases and conditions. The company was founded by Antony E. Pfaffle on July 28, 2006 and is headquartered in Berkeley Heights, NJ.

CorMedix Inc

DaVitas warning that DefenCath reimbursement could fall sharply in 2027 has fueled concern about pricing and sales for CorMedixs flagship product, alongside a steep selloff. Traders disagree over whether the warning signals lasting pressure or is a preliminary, DaVita-specific estimate that overstates the risk; some view the decline as panic selling and point to CMS reimbursement figures as a counterpoint.

Okta, Inc. engages in the provision of an identity management platform for enterprises. The firm operates through the following geographical segments: United States and International. Its products include single sign-on, multi-factor authentication, access gateway, API access management, authentication, adaptive MFA and lifecycle management. The company was founded by Todd McKinnon and J. Frederic Kerrest in 2009 and is headquartered in San Francisco, CA.

Okta Inc - Ordinary Shares - Class A

Okta Inc

Oktas selection for S&P 500 inclusion is drawing attention, with traders anticipating demand from index-tracking funds while debating whether that buying is already priced in and could be followed by profit-taking. The discussion also weighs the inclusion-driven momentum against concerns about Oktas valuation and slower growth.

NEOS ETF Trust - NEOS Nasdaq 100 High Income ETF

NEOS Nasdaq 100 High Income ETF

A broader market and Nasdaq-led tech selloff has pressured QQQI, prompting many holders to add on the dip while others raise cash or worry about further downside. The debate is set against the ETFs appeal as a high-income, monthly-distribution fund and concerns that covered-call exposure can limit upside or leave the fund vulnerable in a downturn.

Cameco Corp. engages in the provision of uranium. It operates through the following segments: Uranium and Fuel Services. The Uranium segment is involved in the exploration for, mining, milling, purchase, and sale of uranium concentrate. The Fuel Services segment deals with the refining, conversion, and fabrication of uranium concentrate and the purchase and sale of conversion services. The company was founded in 1988 and is headquartered in Saskatoon, Canada.

Cameco Corp.

Camecos Q3 report, including lower results and narrowed 2026 production guidance amid Cigar Lake production concerns, is driving the selloff. Traders are split between viewing the update and uranium-sector weakness as reasons for further downside and treating the pullback as an opportunity, citing long-term nuclear demand and firm uranium prices.

Agenus, Inc. is a clinical-stage company, which engages in the development and commercialization of technologies to treat cancers and infectious diseases. Its product pipeline includes Balstilimab, Zalifrelimab, AGEN1181, AGEN1327, AGEN2373, AGENt-797 and AGEN1777. The company was founded by Garo H. Armen and Pramod K. Srivastava on March 31, 1994 and is headquartered in Lexington, MA.

Agenus Inc

Agenus is drawing attention for encouraging early BOT+BAL immunotherapy data, including high pathologic response rates in a small Phase 2 colon cancer cohort and reported activity in sarcoma. The community is divided: bulls see potential for the treatment and its broader platform, while skeptics point to small, nonrandomized studies, the need for Phase 3 validation, and dilution and execution concerns.

Mattel, Inc. engages in the ownership of children's and family entertainment franchises. It operates through the following segments: North America, International, and American Girl. The North America and International segments focus on marketing and selling toys and consumer products. The American Girl segment includes marketing, retailing, and publishing dedicated to its mission to help girls grow up with confidence and character. The company was founded by Elliot Handler, Ruth Handler, and Harold Matson in 1945 and is headquartered in El Segundo, CA.

Mattel, Inc.

Reported takeover interest from Authentic Brands Group, alongside activist pressure for Mattel to consider a sale, is driving the discussion; no formal deal is confirmed. Traders are weighing potential acquisition upside against the risk that the takeover buzz fades without a firm bid.

United States Natural Gas Fund LP. - United States Natural Gas Fund

United States Natural Gas Fund, LP

Mild-weather forecasts and ample storage are weighing on natural gas prices by tempering expectations for heating demand. Traders are split between bearish views citing a potentially warm winter and surplus inventories, and dip-buyers betting on colder forecasts or a winter-driven rebound.

FuelCell Energy, Inc. is an American clean energy technology company that delivers continuous, scalable baseload power for mission-critical applications globally. It engages in the development, design, production, construction, operation, and servicing of high-temperature fuel cells for clean electric power generation. The company’s fuel cell systems generate electricity directly at the point of use, enabling reliable, low-emission power for data centers, industrial facilities, utilities, and distributed generation customers. FuelCell Energy delivers commercially proven, modular, utility-scale systems backed by global fuel cell deployments approaching one gigawatt. The company was founded by Bernard Baker and Martin G. Klein in 1969 and is headquartered in Danbury, CT.

Fuelcell Energy Inc

FCEL is under pressure after traders criticized CEO Jason Fews Bloomberg appearance and flagged his expectation of a delay in signing the Texas definitive contract, alongside uncertainty about the promised 100 MW production ramp. Some investors remain focused on potential data-center demand and the Newport project, while others say execution delays and weak shareholder communication are undermining confidence.

Gorilla Technology Group, Inc. engages in the provision of video intelligence, Internet of Things (IoT) security, edge AI data analytics, and operational technology security solutions and services in Asia Pacific. It operates through the following segments: Video IoT, Security Convergence, and Other. The company was founded by Spincer Koh in May 2001 and is headquartered in London, the United Kingdom.

Gorilla Technology Group Inc

A newly disclosed convertible-note financing and proposed increase in authorized shares have fueled concerns about heavy dilution, triggering sharp selling and criticism of managements communication. Some traders see the funding as necessary to advance data-center projects, while others worry that ongoing cash needs could bring further dilution.

The Walt Disney Co. engages in the business of international family entertainment and media enterprise. It owns and operates television and radio production, distribution and broadcasting stations, direct-to-consumer services, amusement parks, and hotels. It operates through the following business segments: Disney Entertainment, ESPN, and Disney Parks, Experiences, and Products. The company was founded by Walter Elias Disney on October 16, 1923 and is headquartered in Burbank, CA.

Walt Disney Co (The)

Walt Disney Co

Disneys better-than-expected quarterly results, supported by parks strength and improving streaming profitability, have renewed bullish interest and fueled breakout chatter. Traders remain divided, with optimists pointing to stronger execution and skeptics citing years of range-bound performance and nearby resistance.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

RARE's Fayuvi Approval Spurs Second PRV Sale Worth $203M in a Week

Ultragenyx agrees to sell its Fayuvi-linked PRV for $203 million, marking its second voucher sale in one week and adding non-dilutive funding for rare-disease programs.

Here's Why You Should Add ANRO Stock to Your Portfolio Now

Alto advances its depression drug pipeline, with key 2027 study results ahead for ALTO-207, ALTO-300 and ALTO-100.

Syndax Stock Falls 16% as Phase II Fibrosis Study Misses Primary Goal

SNDX shares plunge 16% as its phase II axatilimab study misses the primary endpoint, prompting the company to abandon development in idiopathic pulmonary fibrosis.

Prime Medicine Stock Rallies Nearly 26% in a Month: Here's Why

PRME shares jump nearly 26% in a month as FDA clearance for PM647 and PM577a's clinical debut advances its gene-editing pipeline.

PMVP Stock Rises 19% in 3 Months: Here's What You Need to Know

PMV Pharmaceuticals gains on promising rezatapopt data in ovarian cancer, FDA support for accelerated approval and a planned 2027 NDA filing.

argenx Meets Primary Endpoint in Phase II Celiac Disease Study

ARGX's FB102 achieves its primary endpoint in a phase II celiac disease study, paving the way for late-stage development despite a nearly 12% stock drop.

EDIT Set to Begin First-in-Human Study in Hypercholesterolemia 

Editas Medicine gains approval to launch the first-in-human phase I/II study of EDIT-401 in Australia, targeting LDL cholesterol through gene editing.

Here's Why You Should Add LPCN Stock to Your Portfolio Now

Lipocine's Tlando royalties, Brlizio's phase III trial and broader pipeline offer multiple potential growth drivers and catalysts.

Ultragenyx to Sell Rare Pediatric Disease PRV for $210M to Boost Cash

RARE enters into an agreement to sell a Rare Pediatric Disease PRV for $210M, adding non-dilutive cash as it advances rare-disease therapies.

ETON Stock Surges 108% in Six Months: Here's What You Need to Know

Eton's sales surge, raised 2026 outlook and expanding rare-disease portfolio are boosting confidence in its growth.

Aldeyra Therapeutics, Inc. is a biotechnology company, which engages in research and development activities related to general business planning, including raising capital. It focuses on the discovery of therapies designed to treat immune-mediated diseases. The company was founded by Thomas A. Jordan and John E. Dowling on August 13, 2004 and is headquartered in Lexington, MA.

Aldeyra Therapeutics Inc

Why Did ALDX Stock Tank 70% Today?

Equity

Bearish Sentiment

<ul class="summary-bullets"><li>FDA said the application has failed to demonstrate efficacy in adequate and well controlled studies in the treatment of signs and symptoms of dry eye disease.</li><li>"Inconsistency of study results raises serious concerns about the reliability and meaningfulness of the positive findings,” the FDA said.</li><li>Aldeyra does not plan to conduct additional trials and will instead request a Type A meeting with the FDA.</li></ul>Shares of Aldeyra Therapeutics Inc. (ALDX) plummeted nearly 70% on Tuesday, after the U.S. Food and Drug Administration issued a complete response letter stating insufficient and inconsistent clinical data for the company’s dry eye treatment.The latest update generated a significant buzz on Stocktwits, with retail sentiment for <a href="https://stocktwits.com/symbol/ALDX">ALDX</a> on flipping to ‘bearish’ from ‘bullish’ a day earlier. Message volumes on the platform were ‘extremely high.’<img src="https://news.stocktwits-cdn.com/ALDX_jpg_da5adae775.webp" alt="ALDX.jpg"><h2 class="st-heading-2">FDA Says&nbsp;Inconsistencies Raises Serious Concerns&nbsp;</h2>Responding to the company’s application for reproxalap, the FDA cited “a lack of substantial evidence consisting of adequate and well-controlled investigations … that the drug product will have the effect it purports or is represented to have under the conditions of use prescribed, recommended, or suggested in its proposed labelling.”The letter also read “the application has failed to demonstrate efficacy in adequate and well controlled studies in the treatment of signs and symptoms of dry eye disease.”&nbsp;The FDA stated “inconsistency of study results raises serious concerns about the reliability and meaningfulness of the positive findings” and that the “totality of evidence from the completed clinical trials does not support the effectiveness of the product.”&nbsp;<h2 class="st-heading-2">What Did The FDA Recommend?</h2>The FDA advised analyzing why certain trials failed and identifying specific patient groups or conditions where reproxalap may be effective. The administration did not recommend conducting additional trials or request submission of additional evidence.As per prior NDA reviews of the drug, no safety or manufacturing concerns were identified, the company added.Aldeyra said that it does not plan to conduct additional trials and will instead request a Type A meeting with the FDA to determine the steps needed for approval.<h2 class="st-heading-2">What Did Stocktwits Users Say?</h2>One user said the FDA’s response essentially means “back to square one” for the company.<stembedurl>https://stocktwits.com/FadG/message/647744708</stembedurl>Another user said the field trial is what&nbsp;“did them in.”<stembedurl>https://stocktwits.com/bobbyhughes611/message/647731037</stembedurl>Year-to-date the stock has declined around 75%.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Aldeyra Therapeutics logo is seen displayed on the screen of a tablet. (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images)

The U.S. FDA rejected Aldeyra’s application for a dry eye drug, citing a “lack of substantial evidence.”

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Current Price	$0.5603
Prev Close	$0.6591
Open	$0.67
Dividend Yield	0.00%
50-Day Moving Average	$1.15
Beta	3.01
Avg. Volume	958,556.07
PE Ratio	-1.46

52-Week High	$5.93
52-Week Low	$0.5502
Market Capitalization	$33.8M
EPS (Annual)	-$0.5636
Price to Book	0.89
Revenue Per Employee	$0.00

Feed

News

Sentiment

Earnings

Fundamentals

Info

ALDX Fundamentals